Free
Correspondence  |   October 2011
In Reply
Author Affiliations & Notes
  • Brendan Carvalho, M.B.B.Ch., F.R.C.A.
    *
  • *Stanford University Medical Center, Stanford, California.
Article Information
Correspondence
Correspondence   |   October 2011
In Reply
Anesthesiology 10 2011, Vol.115, 900. doi:10.1097/ALN.0b013e31822c656b
Anesthesiology 10 2011, Vol.115, 900. doi:10.1097/ALN.0b013e31822c656b
We would like to thank Dr. Nathan L. Pace for his commentary and additional analysis of our study.1 We agree that entire dose-response curve analysis does permit a more robust statistical comparison than ED50and ED95single-point comparisons. Dr. Pace's reanalysis found ED50and ED95values similar to our original calculations. We concur with the differences Dr. Pace found in the dose-response curves, noting higher dose requirements in this morbidly obese population compared with a nonobese population studied previously. Despite evidence of different dose-responses and higher ED50values in morbidly obese patients, we are hesitant to firmly conclude that obese patients require larger intrathecal doses of local anesthetics compared with nonobese patients for a number of reasons:
The primary objective of our study was to determine the ED50and ED95in our morbidly obese population. Comparisons of ED50and ED95values of these morbidly obese patients with those of a nonobese population previously studied by our group were only a secondary analysis and study endpoint. In addition, using historical controls from a number of years ago presents important limitations, as we mentioned in our manuscript. Historical controls are associated with many confounders and biases that may affect group comparisons. Both studies contained small study populations (42 morbidly obese and 42 nonobese patients); therefore, a few individuals can have a greater influence on the overall population dose-response curve than preferable. In addition, although we followed a methodology similar to that of the previous study, it was not identical (e.g.  , 5–11 mg doses administered in the obese population were compared with 6–12 mg doses in nonobese patients).
While we acknowledge Dr. Pace's analysis of a rightward shift in the dose-response curves of the morbidly obese population compared with a nonobese population, the limitations noted above remain. We therefore do not want to go as far as recommending increasing the intrathecal local anesthetic dose in the morbidly obese patients undergoing cesarean delivery. It is worth noting that no patient in our study received the calculated ED95of 14.3 ± 0.9 mg, and we can therefore not comment on its safety. In contrast to expert advice, our study does suggest that the intrathecal bupivacaine dose should not be reduced for obese patients. Our findings also imply that morbidly obese patients are not well-suited to a single-shot spinal technique. More variable responses to intrathecal dosing and longer surgical times indicate that catheter-based techniques are more appropriate. Our study also highlights that initial satisfactory sensory block to pinprick following small intrathecal doses does not ensure adequate intraoperative anesthesia for the duration of the surgical procedure.
Reference
Reference
Carvalho B, Collins J, Drover DR, Atkinson Ralls L, Riley ET: ED50and ED95of intrathecal bupivacaine in morbidly obese patients undergoing cesarean delivery. ANESTHESIOLOGY 2011; 114:529–35